TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percent of Participants With PHQ-9 Score ≥ 10
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of self-reported lifetime testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ASCVD risk score at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Hypoglycemic Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: OSA prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in VAS Pain Scale Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alkaline Phosphatase (ALP) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Percentage of Participants With HIV-1 RNA <50 c/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with a soft tissue mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bronchodilator Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Treatment efficacy of 15% glycolic acid lotion for flat warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Safety and tolerability of 15% glycolic acid lotion for flat warts
Endpoint domain: Adverse events/effects
Primary endpoint: Major Pathologic Response Rate (MPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Distant-metastasis free survival (DMFS)
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline Trough in 24-hour Weighted Mean FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cardiovascular intensity (metabolic Units)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiovascular intensity (Percent of maximum heart rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Borg Rate of Perceived Exertion Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Percentage of Participants With Treatment-Emergent Sinus Bradycardia Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Treatment-Emergent Sinus Tachycardia Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Other Treatment-Emergent Cardiac Arrhythmia Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of post-spinal anesthesia hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Hamilton Depression Rating Scale (HDRS) Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Headaches per week
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: total weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: excess weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscular mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in PBMC gene expression profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in gait speed (m/sec)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major ICD-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Neurocognitive functions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: occurrence rate of clinically significant CMV viremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: BMI percentile at 12 months of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BMI percentile at 24 months of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Place of death
Endpoint domain: Mortality/survival
Primary endpoint: Change in Visual Analogue Scale for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quality of Life at 4 weeks
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Quality of Life at 26 weeks
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pathologic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of Grade 3 or higher xerostomia
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first Disease Related Event
Endpoint domain: Mortality/survival
Primary endpoint: Aqueous humor glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Radiographic cup abduction angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Radiographic cup anteversion angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Subject deaths
Endpoint domain: Mortality/survival
Primary endpoint: Cardiomyopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Depression Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Serum Osteocalcin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patients not treated with corticosteroids at day 7
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of death during follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Biochemically Verified 7-day Point Prevalence Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum observed plasma concentration (Cmax) of GLPG2737 and its metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of occurrence of Cmax for GLPG2737 (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve for GLPG2737 (AUC0-24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in limits of stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Nine hole peg Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New-onset diabetic foot
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: decisions of limitations and therapeutic stops
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of Investigator's Global Assessment score (IGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Post-Prandial Glucose AUC 2-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients without parasitaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence/severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Renal Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Bladder Capacity (mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Richmond Agitation-Sedation Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average of Daily Rhinoconjunctivitis Symptom Score (RSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of levels of DNA adducts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of levels of tobacco specific nitrosamines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of levels of stress hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of levels of DNA methylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of SDRT ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed Cerebral Ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Y-balance score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cough reflex sensitivity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abstinence From Smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Needs of CF adolescents and their parents before transition
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Experience of CF adolescents and their parents after transition
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Completion of patient-dependent pathway interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Outcome of standardized food challenges
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentrations of sexual steroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Intra-tissue concentrations of sexual steroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mortality during the COVID-19 treatment hospital encounter
Endpoint domain: Mortality/survival
Primary endpoint: ICU admission during the COVID-19 treatment hospital encounter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilator use during the COVID-19 treatment hospital encounter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of elevated liver function tests
Endpoint domain: Adverse events/effects
Primary endpoint: Serum concentration of c-reactive protein (CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of Pain Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical pregnancy rate at 8 -10 weeks gestational age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Improvement by global assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: PONV prophylaxis efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of reminders triggered during Virtual Health Checks
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in PTSD Checklist for DSM-5 (PCL-5) From Baseline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Patient Health Questionnaire-9 (PHQ-9) From Baseline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Salimetrics Salivary Cytokine Panel From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of Debio 1450 and Debio 1452
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of maximum observed plasma concentration (tmax) of Debio 1450 and Debio 1452
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) of Debio 1450 and Debio 1452
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Hypoxemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Changes in Target Effect Site Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of subcutaneous injections
Endpoint domain: Adverse events/effects
Primary endpoint: HIV testing ever
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: HIV testing frequency
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change score in liking/wanting of e-cigarette
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postoperative days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: global longitudinal peak systolic strain (GLPSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: self-reported context-specific sitting time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Methadone Pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient-reported Symptoms of Varicose Veins (VVSymQ Score)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complicated Grief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cognitive function in response to heavy drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive function in response to sleep quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Self-reported residual effects of heavy drinking
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: ALSFRS-R Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Slow Vital Capacity Score (SVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: composite of death and cardiac events
Endpoint domain: Mortality/survival
Primary endpoint: Steen Happiness Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: lung tissue concentration of ceftazidime
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of AAD (Acute Antibiotic-Associated Diarrhea)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Choking episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Longitudinal Growth as Measured by Height Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of unsuccessful LND along the left RLN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Korean Version of Montreal Cognitive Assessment (MoCA) score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Single photon emission computed tomography (SPECT) z-score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: The verbal learning test (VLT) score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area under curve and maximal plasmatic level of troponin-T
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under curve and maximal plasmatic level of NT-pro-BNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under curve and maximal plasmatic level of creatine kinase-MB (CK-MB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of participants with protective immunity against HBV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent Change in Insulin Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Change in Localized Muscle Lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in umami taste intensity perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in umami taste discrimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suicide severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Pre-Dose Pre-Bronchodilator FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fibromyalgia Impact Questionnaire, Revised (FIQ-R) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Regression of high risk proliferative diabetic retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Re-eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of symptoms related to peripheral neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Chromosomal status of the embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Marrow and Peripheral Blood Chimerism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Velocity sedimentation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total score of BSS (Bronchitis Severity Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Absorption constant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of responders for more than 5 serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PIV Catheter complication rates
Endpoint domain: Adverse events/effects
Primary endpoint: TCR repertoire analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Motion parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Clinical Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary Safety Composite
Endpoint domain: Adverse events/effects
Primary endpoint: Admission to the hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reduction of hospitalization for acute heart failure
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: liver inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: liver steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of fat processed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute technical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: initial performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the percentage of transferrin saturation in the participants' blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Effectiveness at 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with disease recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Change in Toronto Western Spasmodic Torticollis Rating Scale Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Upper extremity volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signs and symptoms of acute infection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: biologically verified smoking cessation or reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adipokines Plasma Levels (Adiponectin, Leptin, Resistin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting Blood Glucose Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HOMA-IR (Homeostasis Model Assessment of Insulin Resistance) Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metabolic Syndrome Z Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Ball Throwing Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Standing Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropathic Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Energy expenditure (resting)/Meal-induced thermogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Radical resection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: patient response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in urinary albumin-to-creatinine ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in total bacterial population in the bronchoalveolar lavage fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes